antimuscarinic


Also found in: Wikipedia.

antimuscarinic

 [an″te-, an″ti-mus″kah-rin´ik]
1. effective against the toxic effects of muscarine.
2. blocking the muscarinic receptors.
3. an agent that counteracts the effects of muscarine or blocks the muscarinic receptors.

an·ti·mus·ca·rin·ic

(an'tē-mŭs'kă-rin'ik),
Inhibiting or preventing the actions of muscarine and muscarinelike agents, or the effects of parasympathetic stimulation at the neuroeffector junction (for example, atropine).

antimuscarinic

/an·ti·mus·ca·rin·ic/ (an″te-) (an″ti-mus´kah-rin´ik)
1. effective against the toxic effects of muscarine.
2. blocking the muscarinic receptors.
3. an agent having either such action.

antimuscarinic

[-mus′kərin′ik]
Etymology: Gk, anti + L, musca, fly
effective against the poisonous activity of muscarine. Compare muscarinic.
References in periodicals archive ?
The treatments described on steps 4 and higher are maintenance treatment with at least medium to high doses of inhaled corticosteroid with one or more additional controller medications, which may include a long-acting beta-2-agonist (LABA), a long-acting antimuscarinic (tiotropium has recently been approved in many countries for the treatment of severe asthma), [2] slow-release theophylline, and a leukotriene modifier (montelukast).
The BESIDE results appear to indicate that adding mirabegron therapy, a Beta-3 adrenergic agonist, to solifenacin therapy, an antimuscarinic, may offer relief from the burden of OAB," said Professor Marcus Drake, MA, DM, FRCS (Urol), University of Bristol and Bristol Urological Institute, Bristol, UK.
The Grant will fund the project titled 'An Imaging Biomarker for Bladder Activity Disorders: Functional Magnetic Resonance 7 Tesla Imaging ( fMRI) in combination with urodynamics to study the effect of bladder sensory stimulation on brain activity in patients with a Bladder activity disorder, including the effect of antimuscarinic and beta mimetic agents'.
Second-line treatments include oral antimuscarinic drugs or mirabegron, preferably in an extended-release formulation if available to reduce the likelihood of dry mouth from immediate-release formulations.
Timing and frequency of physostigmine redosing for antimuscarinic toxicity.
Pirenzepine is also an antimuscarinic drug which has been used in the treatment of myopia progression.
Scopolamine is an antimuscarinic agent with a potent action on salivary glands; it can reduce the volume of salivary secretion in human beings.
Also, some of the newer long-acting antimuscarinic agents (LAMAs) include drugs such as aclidinium and glycopyrrolate.